GRAIL (GRAL) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and market opportunity

• Positioned as a leader in multi-cancer early detection (MCED) with a first-mover advantage and FDA breakthrough designation.

• Galleri test targets a global market exceeding 300 million people across the U.S., U.K., E.U., and Japan.

• Commercial partnerships span health systems, employers, insurers, and telemedicine platforms.

• Over 290,000 commercial tests completed, with strong repeat testing rates and growing provider adoption.

• Focused on achieving FDA approval, broad reimbursement, and population-scale screening.

Technology, clinical evidence, and implementation

• Galleri uses a methylation platform to detect cancer signals across multiple types, with high specificity and positive predictive value (PPV).

• PATHFINDER study showed Galleri more than doubled cancer detection versus standard screening, with 43% PPV.

• High localization accuracy enables efficient diagnostic workups; no serious adverse events reported.

• New test version is fully automated, increases lab efficiency, and reduces sequencing costs.

• Updated test report simplifies cancer signal origin classification for physicians.

Financial performance and operational efficiency

• 2024 revenue expected at $124–$126 million, up 34% year-over-year; U.S. sales up 45%.

• Cash balance of $767 million, with runway into 2028; 2024 cash burn was $579 million.

• Second-half 2024 cash burn reduced to under $200 million, below guidance.

• 2025 U.S. Galleri business projected to grow 20–30%, with cash burn capped at $320 million.

• No additional CapEx needed for several years due to expanded lab automation and capacity.